Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1539 of 5804
-
New drug AOC 1001 tested for rare muscle disease
Disease control CompletedAOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARIN…
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New TB drug combo shows promise in early trial
Disease control CompletedThis trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone
Phase: PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC
-
Virus-Immunotherapy cocktail takes on tough GI cancers
Disease control OngoingThis is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate \[ORR; Cohorts 1,2, 4,and 5\] and disease control rate \[DCR; Cohort 3\]) in patients…
Phase: PHASE1, PHASE2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Frozen platelets could be just as good as fresh ones for heart surgery bleeding
Disease control CompletedA randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.
Phase: PHASE2, PHASE3 • Sponsor: Cellphire Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control CompletedThe Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembroliz…
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Lifestyle overhaul may cut dementia risk in latin america
Prevention CompletedCurrently, 40% of global dementia cases can be prevented through lifestyle changes, with Latin America having a 56% potential reduction due to its high-risk factors. At the moment, there are no medications that halt the clinical expression of dementia. LatAm-FINGERS, a multicent…
Phase: NA • Sponsor: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New hope for kids with rare muscle disease: drug trial launches
Disease control Recruiting nowThe purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximate…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Monthly shot study tests better doses for opioid addiction
Disease control CompletedThe primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine. The primary objective of the maintenance phase is to compare the efficac…
Phase: PHASE4 • Sponsor: Indivior Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors
Phase: PHASE1, PHASE2 • Sponsor: Advenchen Laboratories, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New flavored chemo drink aims to ease treatment for kids with hard-to-treat cancers
Disease control OngoingA pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarco…
Phase: PHASE1 • Sponsor: Valent Technologies, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a Two-Drug cocktail replace triple therapy for heart stent patients?
Disease control Recruiting nowMore than 25% of patients referred for diagnostic coronary angiography and percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS) suffer from non-valvular atrial fibrillation (AF). In this particular setting, balancing between the prevention of thrombosis a…
Phase: PHASE4 • Sponsor: Medical University of Gdansk • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New oral combo aims to keep leukemia at bay after remission
Disease control Recruiting nowThis phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Phase: PHASE2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat psoriatic arthritis
Disease control CompletedThe purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical r…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a zapping headband tame tough seizures?
Symptom relief CompletedThis is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (…
Phase: NA • Sponsor: Neuroelectrics Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Pacemaker tweak may quietly lower blood pressure without extra pills
Disease control CompletedThis washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately. Patients will have their PHC programmed to automatical…
Phase: PHASE1, PHASE2 • Sponsor: BackBeat Medical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a fiber supplement boost Metformin's power in obese teens?
Disease control Recruiting nowThis is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation …
Phase: PHASE3 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control CompletedThis Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Phase: PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Triple-Drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThe main objective of the study is to establish if patients with advanced bile duct cancer, who have already received a line of treatment for their disease, will receive any associated benefits from the combination of mFOLFOX6, bevacizumab and atezolizumab as a second-line therap…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo pill tested for long-term safety in teens with mental health conditions
Disease control ENROLLING_BY_INVITATIONTo evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC